Search research articles
Contact Us
Filters
Showing results (61-70 of 103) with videos related to
Page
of 11
Sort By:
British Journal of Clinical Pharmacology
|
August 8, 2001
First results from an intensified monitoring system to estimate drug related hospital admissions
S Schneeweiss, M Göttler, J Hasford, et al.
Annals of Hematology
|
February 26, 2003
German multicenter study group for adult ALL (GMALL): recruitment in comparison to ALL incidence and its impact on study results
M Dugas, D Messerer, J Hasford, et al.
Endoscopy
|
November 11, 2005
The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies
W Heldwein, M Dollhopf, T Rösch, et al.
Zeitschrift Fur Gerontologie Und Geriatrie
|
August 16, 2011
The LUCAS* consortium: objectives of interdisciplinary research on selected aspects of ageing and health care for older people in an urban community
W von Renteln-Kruse, U Dapp, J Anders, et al.
Zeitschrift Fur Gerontologie Und Geriatrie
|
January 25, 2012
[The Longitudinal Urban Cohort Ageing Study (LUCAS)]
U Dapp, R Fertmann, J Anders, et al.
Journal of the National Cancer Institute
|
June 13, 1998
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group
J Hasford, M Pfirrmann, R Hehlmann, et al.
Journal of Interferon Research
|
August 1, 1994
Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia
P Von Wussow, R Hehlmann, T Hochhaus, et al.
Blood
|
December 15, 1994
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group
R Hehlmann, H Heimpel, J Hasford, et al.
Expert Opinion on Drug Safety
|
December 21, 2017
Preventable ADRs leading to hospitalization - results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients
S Schmiedl, M Rottenkolber, J Szymanski, et al.
Blood
|
July 15, 1993
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
R Hehlmann, H Heimpel, J Hasford, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 103) with videos related to
Sort By:
Page
of 11
British Journal of Clinical Pharmacology
|
August 8, 2001
First results from an intensified monitoring system to estimate drug related hospital admissions
S Schneeweiss, M Göttler, J Hasford, et al.
Annals of Hematology
|
February 26, 2003
German multicenter study group for adult ALL (GMALL): recruitment in comparison to ALL incidence and its impact on study results
M Dugas, D Messerer, J Hasford, et al.
Endoscopy
|
November 11, 2005
The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies
W Heldwein, M Dollhopf, T Rösch, et al.
Zeitschrift Fur Gerontologie Und Geriatrie
|
August 16, 2011
The LUCAS* consortium: objectives of interdisciplinary research on selected aspects of ageing and health care for older people in an urban community
W von Renteln-Kruse, U Dapp, J Anders, et al.
Zeitschrift Fur Gerontologie Und Geriatrie
|
January 25, 2012
[The Longitudinal Urban Cohort Ageing Study (LUCAS)]
U Dapp, R Fertmann, J Anders, et al.
Journal of the National Cancer Institute
|
June 13, 1998
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group
J Hasford, M Pfirrmann, R Hehlmann, et al.
Journal of Interferon Research
|
August 1, 1994
Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia
P Von Wussow, R Hehlmann, T Hochhaus, et al.
Blood
|
December 15, 1994
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group
R Hehlmann, H Heimpel, J Hasford, et al.
Expert Opinion on Drug Safety
|
December 21, 2017
Preventable ADRs leading to hospitalization - results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients
S Schmiedl, M Rottenkolber, J Szymanski, et al.
Blood
|
July 15, 1993
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
R Hehlmann, H Heimpel, J Hasford, et al.
Page
of 11